Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

Innovation Action · Running

REPRODIVAC Next-generation vaccines and diagnostics to prevent livestock reproductive diseases of worldwide impact

Coordinator
Agenzia Nazionale per Le Nuove Tecnologie, L'energia E Lo Sviluppo Economico Sostenibile, Italy
Runs
1 September 2022 to 31 August 2027
Status
Running
EU funding
€3.1m
Total cost
€3.1m
Partners
18 organisations in 8 countries
Type
Innovation Action
Grant agreement
101060813

What the project is doing

In the project's own words, from its summary on CORDIS.

Endemic and zoonotic infectious reproductive diseases of livestock cause major economic losses globally and threaten both food security and public health. REPRODIVAC will develop new and improved vaccines and diagnostic tools required to better control four priority abortifacient diseases: porcine reproductive and respiratory syndrome (PRRS), Q fever, ovine enzootic abortion (OEA), and porcine brucellosis. The consortium spans academia and industry with complementary expertise including structural biology, microbiology, immunology, plant and veterinary sciences.

This enables us to address reproductive disorders with an interdisciplinary approach: (1) applying reverse and structural vaccinology to select and design vaccine and diagnostic candidate antigens; (2) exploiting relevant protein expression systems for the production of these antigens; (3) producing rationally attenuated and viral vectored vaccines; and (4) developing a suite of molecular and immunological diagnostic tests, including point-of-care tests (PoC) to discriminate vaccinated from infected animals (DIVA).

We will develop a broadly protective PRRSV vaccine, and a serological ELISA that will reliably correlate with PRRSV neutralising antibody titres. We will identify protective subunit vaccine candidates for Q fever and validate a companion serological DIVA test. We will further refine an OEA vaccine for commercialisation and pursue a complementary approach towards a DIVA-compatible next-generation subunit vaccine and serological and molecular DIVA/PoC tests.

We will develop live attenuated Brucella suis vaccines and brucellosis diagnostic tests with improved specificity. These new vaccines and diagnostics will be further developed by our industrial partners and made accessible to users. Thereby by using the latest technologies in vaccine and diagnostic development REPRODIVAC will improve animal health and welfare, productivity and sustainability of the livestock sector, as well as human health.

Topics

Who is involved

OrganisationCityCountryRole
Agenzia Nazionale per Le Nuove Tecnologie, L'energia E Lo Sviluppo Economico SostenibileRomaItalyCoordinator
Veterinaermedizinische Universitaet WienWienAustriaParticipant
Ecole Polytechnique Federale De LausanneLausanneSwitzerlandAssociatedpartner
Friedrich Loeffler Institut - Bundesforschungsinstitut Fuer TiergesundheitGreifswald-Insel RiemsGermanyParticipant
Associacio Porcsa - Grup De Sanejament Porci De LleidaLleidaSpainAssociatedpartner
Centro De Investigacion Y Tecnologia Agroalimentaria De AragonZaragozaSpainParticipant
Consorcio Centre D'estudis PorcinsTorrelameuSpainThird party
Cz Vaccines SAPorrinoSpainAssociatedpartner
Universidad De LleidaLleidaSpainParticipant
Universidad De MurciaMurciaSpainParticipant
Universidad De NavarraPamplonaSpainParticipant
Ceva Sante Animale SALibourneFranceParticipant
Ecole Normale Superieure De LyonLyonFranceParticipant
Stichting Wageningen ResearchWageningenNetherlandsParticipant
Global DX LtdMenstrieUnited KingdomAssociatedpartner
Moredun Research InstitutePenicuikUnited KingdomAssociatedpartner
The Chancellor, Masters and Scholars of the University of OxfordOxfordUnited KingdomAssociatedpartner
The Pirbright Institute LbgWokingUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI